{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Haemophilia+B+With+Inhibitors&page=2", "query": { "condition": "Haemophilia B With Inhibitors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Haemophilia+B+With+Inhibitors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T12:12:44.567Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04489537", "title": "Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A With Inhibitor", "Hemophilia B With Inhibitor" ], "interventions": [ { "name": "MarzAA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Catalyst Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 18, "start_date": "2021-05-04", "completion_date": "2021-12-01", "has_results": false, "last_update_posted_date": "2021-12-17", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04489537" }, { "nct_id": "NCT00108758", "title": "Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A With Inhibitors", "Haemophilia B With Inhibitors" ], "interventions": [ { "name": "activated recombinant human factor VII", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "MALE", "summary": "2 Years and older · Male only" }, "enrollment_count": 23, "start_date": "2004-03", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 13, "location_summary": "Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108758" }, { "nct_id": "NCT00002386", "title": "Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "Hemophilia A" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Zalcitabine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "MALE", "summary": "16 Years and older · Male only" }, "enrollment_count": 55, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 7, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002386" }, { "nct_id": "NCT05695391", "title": "A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia" ], "interventions": [ { "name": "Coagulation Factor VIIa (Recombinant)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 2, "start_date": "2024-06-07", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 5, "location_summary": "Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695391" }, { "nct_id": "NCT04082429", "title": "Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilia A Without Inhibitors", "Haemophilia B Without Inhibitors" ], "interventions": [ { "name": "Concizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "MALE", "summary": "12 Years and older · Male only" }, "enrollment_count": 156, "start_date": "2019-11-13", "completion_date": "2028-02-21", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 12, "location_summary": "Los Angeles, California • Orange, California • Augusta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082429" }, { "nct_id": "NCT01392547", "title": "Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A With Inhibitors", "Haemophilia B With Inhibitors" ], "interventions": [ { "name": "vatreptacog alfa (activated)", "type": "DRUG" }, { "name": "eptacog alfa (activated)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "MALE", "summary": "12 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2011-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 14, "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01392547" }, { "nct_id": "NCT00882778", "title": "PROPACT: Retrospective Prophylaxis Patient Case Collection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A With Inhibitors", "Haemophilia B With Inhibitors" ], "interventions": [ { "name": "eptacog alfa (activated)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 86, "start_date": "2009-04", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882778" }, { "nct_id": "NCT05789537", "title": "A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophilia B with Inhibitor", "Hemophilia B" ], "interventions": [ { "name": "SerpinPC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ApcinteX Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 3, "start_date": "2023-07-28", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 3, "location_summary": "Aurora, Colorado • Tampa, Florida • Greenville, North Carolina", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05789537" }, { "nct_id": "NCT01561391", "title": "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Congenital Bleeding Disorder", "Haemophilia A With Inhibitors", "Haemophilia B With Inhibitors" ], "interventions": [ { "name": "activated recombinant human factor VII", "type": "DRUG" }, { "name": "factor IX", "type": "OTHER" }, { "name": "factor VIII", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 36, "start_date": "1998-04", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 14, "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01561391" }, { "nct_id": "NCT01757405", "title": "Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A", "Hemophilia B" ], "interventions": [ { "name": "Recombinant Factor VIIa BI (rFVIIa BI)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 40, "start_date": "2013-02-20", "completion_date": "2014-11-11", "has_results": true, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-06-10T12:12:44.567Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01757405" } ] }